Pfizer (NYSE:PFE) Trading Down 0.2% - Should You Sell?

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price fell 0.2% during mid-day trading on Thursday . The company traded as low as $24.78 and last traded at $24.90. 7,854,625 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 38,309,750 shares. The stock had previously closed at $24.94.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Daiwa America upgraded shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the company a "neutral" rating in a research report on Wednesday, July 31st. Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $32.92.

Pfizer Trading Up 0.4 %

The firm has a market capitalization of $141.90 billion, a PE ratio of 33.65, a PEG ratio of 0.80 and a beta of 0.67. The business has a fifty day moving average price of $28.36 and a two-hundred day moving average price of $28.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's dividend payout ratio (DPR) is currently 227.03%.

Insiders Place Their Bets

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently bought and sold shares of PFE. Morse Asset Management Inc acquired a new stake in shares of Pfizer in the 3rd quarter worth approximately $2,649,000. Diamant Asset Management Inc. grew its position in shares of Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock valued at $246,000 after purchasing an additional 660 shares during the last quarter. Westside Investment Management Inc. increased its position in Pfizer by 7.7% during the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after buying an additional 1,004 shares in the last quarter. Virtu Financial LLC acquired a new position in Pfizer in the 3rd quarter valued at about $1,499,000. Finally, Passumpsic Savings Bank lifted its stake in shares of Pfizer by 8.4% during the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock valued at $743,000 after buying an additional 1,998 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.